Takeda Signs a Licensing Agreement with Curadev for Stimulator of Interferon Genes (STING) Agonist

 Takeda Signs a Licensing Agreement with Curadev for Stimulator of Interferon Genes (STING) Agonist

Takeda Signs a Licensing Agreement with Curadev for Stimulator of Interferon Genes (STING) Agonist

Shots:

  • Takeda enters into a licensing agreement with Curadev for its Stimulator of Interferon Genes (STING) agonist/ CRD5500 and its associated patents
  • The focus of the agreement is to develop immuno-oncology targets, providing one day deliver transformational benefit to patients. Additionally, out-licenses its IP portfolio to Endo, Medivation & Roche
  • Curadev’s CRD5500 is a sting agonist amenable to bioconjugation as an ADC targeting anti-PD-L1/anti-CTLA4/IDO-TDOi, activating human STING variants to shrink tumors and successfully conjugated with trastuzumab

Click here to read full press release/ article | Ref: PRNewsWire | Image: Twitter


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post